Skip to main content
. 2009 Sep 14;101(1):167–172. doi: 10.1111/j.1349-7006.2009.01368.x

Figure 3.

Figure 3

 Effects of dasatinib on growth and apoptosis in gefitinib‐resistant non‐small cell lung cancer cells with MET amplification. (A) HCC827 cells or (B) HCC827 GR5 cells were treated for 72 h with increasing concentrations of gefitinib alone, PHA‐665752 alone, gefitinib and PHA‐665752 in combination, or dasatinib alone in medium containing 10% serum, after which cell viability was assessed. Data are means of triplicates from a representative experiment and are expressed as a percentage of the value for untreated cells. (C) HCC827 and HCC827 GR5 cells were incubated for 72 h with gefitinib (1 μm) alone, PHA‐665752 (1 μm) alone, gefitinib plus PHA‐665752, or dasatinib (1 μm) in medium containing 10% serum. Cell lysates were then prepared and subjected to immunoblot analysis with antibodies to poly(ADP‐ribose) polymerase (PARP) and to β‐actin. The positions of intact PARP (116 kDa) and the 85‐kDa cleavage fragment (c‐PARP) are shown.